Kleileuk (Bendamustine Hydrochloride)

Bendamustine hydro­chloride alkylates DNA, creating cross‑links that block DNA synthesis and transcription. This disruption leads to cell cycle arrest and apoptosis, particularly in rapidly dividing malignant lymphocytes, thereby reducing tumor burden.

The specific dose of Kleileuk is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area, and overall health. Dosing regimens are individualized and should follow the latest clinical guidelines and the prescriber’s judgment.

Safety data for bendamustine during pregnancy and lactation are limited, and the drug is generally contraindicated in these situations. Women of child‑bearing potential should use effective contraception, and breastfeeding should be avoided while receiving treatment. Consultation with a healthcare professional is essential.

To order Kleileuk, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and necessary import documentation.

Kleileuk (bendamustine) combines alkylating activity with a benzimidazole ring, offering a distinct toxicity profile compared with traditional agents like cyclophosphamide. It often provides higher response rates in certain lymphoid malignancies, but clinicians weigh efficacy against side‑effect risks and may combine it with monoclonal antibodies for synergistic effect.

Kleileuk must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect from light, and do not freeze or shake the solution. Prior to administration, allow the product to reach room temperature if required by the preparation protocol.

Kleileuk is given as an intravenous infusion. The prescribed volume is diluted in an appropriate infusion fluid and administered over a specified period, typically 30 minutes to several hours, under medical supervision. Infusion rates and pre‑medication to prevent reactions are determined by the treating physician.

The most serious adverse events include severe infections due to neutropenia, pulmonary toxicity such as interstitial pneumonitis, and the potential development of secondary malignancies. Patients should be monitored closely for signs of infection, respiratory distress, and any new cancerous lesions throughout treatment.

Kleileuk is contraindicated in individuals with known hypersensitivity to bendamustine or any formulation components, those with severe bone‑marrow suppression, active uncontrolled infections, and pregnant or breastfeeding women. Caution is also advised for patients with significant hepatic or renal impairment.